(PRWEB) December 22, 2013
The federal litigation established for Byetta lawsuits (http://www.byettalawsuit2013.com/), which also includes claims brought by users of several other diabetes medications, continues to progress in the U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports.
According to a recent update from the U.S. Judicial Panel on Multidistrict Litigation, a total of 163 cases had been filed in the federal proceeding as of December 16th. Cases involved in this litigation similarly allege pancreatitis, pancreatic cancer and thyroid cancer caused by Byetta, Januvia and other medications belonging to a class of Type 2 diabetes drugs referred to as incretin mimetics. Plaintiffs in these lawsuits claim that manufacturers failed to warn doctors and patients about the alleged pancreatic side effects that may occur after use of their products. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“As our Firm continues to investigate potential claims on behalf of individuals who may have experienced the serious pancreatic side effects associated with Byetta, we are not at all surprised to see the number of cases filed in the federal litigation continuing to grow,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential Byetta lawsuit reviews to individuals who may have been injured by the Type 2 diabetes medication.
Following Byetta’s approval in 2005, the medication has been at the center of several public health warnings from the U.S. Food and Drug Administration (FDA), not to mention a growing number of lawsuits that allege serious pancreatic side effects. Those concerns began in 2008, when the federal agency released a Drug Safety Communication that focused on the multiple reports of Byetta pancreatitis it had received from individuals who took the incretin mimetic.* In February 2011, the findings of a study published in Gastroenterology revealed that patients taking this medication may be three times more likely to develop pancreatic cancer, and six-times more likely to develop pancreatitis than those who did not. The research also showed 30 instances of thyroid cancer in Byetta users.**
Following these revelations, the FDA announced in March 2013 that it had begun to investigate findings of a previously unpublished study that showed precancerous changes in the pancreatic cells of incretin mimetic users. Though the agency has not yet reached a conclusion on this matter, the review continues to remain active.
Court records indicate that claims of Byetta causing pancreatic cancer and pancreatitis, as well as other cases involving similarly-designed diabetes drugs, are continuing to move forward. In the federal litigation underway in California, two “Science Days” to review scientific and medical issues that may arise in the proceeding have been scheduled for February 2014. Among other matters, parties will discuss the nature of Type 2 diabetes, as well as the role of incretin mimetics in treating the disease, and data looking at the effects they may have on the pancreas. According to a court order issued last month, these “Science Days” will take place on February 5 and 6, 2014.
If you developed pancreatic cancer, pancreatitis or thyroid cancer after taking Byetta, you may be eligible to receive compensation for damages incurred by your injuries. Learn more about the association between Byetta and pancreatic cancer when you visit Bernstein Liebhard LLP’s website, or by calling the Firm directly for a free and confidential case review at 800-511-5092.
*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm,FDA, August 18, 2008
**gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com